SRPT241122C119000
- 0.51
- 0.000.00%
Sarepta Therapeutics Newsroom
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Analyst Expectations For Sarepta Therapeutics's Future
Sarepta Therapeutics Analyst Ratings
H.C. Wainwright Initiates Sarepta Therapeutics(SRPT.US) With Sell Rating, Announces Target Price $80
Express News | Sarepta Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Sell Rating and Target Price $80
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $197
J.P. Morgan Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Express News | Sarepta Therapeutics Inc : JP Morgan Cuts Target Price to $197 From $202
S&P 500 Futures Climb In Premarket Trading; Target, Fabrinet Lag
Barclays Initiates Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $209
High Alpha Stocks That Are Rated 'Overweight' – MS
Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $210
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
Buy Rating on Sarepta Therapeutics: Confidence in Elevidys' Market Potential and Strategic Expansion
Statutory Earnings May Not Be The Best Way To Understand Sarepta Therapeutics' (NASDAQ:SRPT) True Position
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem
Sarepta's Valuation Seen As An Easy Pill to Swallow -- Market Talk
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating